Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

593
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
593

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cross-talk between cancer and Pseudomonas aeruginosa mediates tumor suppression.

Communications biology·2023
Same author

Bacterial azurin in potential cancer therapy.

Cell cycle (Georgetown, Tex.)·2016
Same author

Structural studies on Laz, a promiscuous anticancer Neisserial protein.

Bioengineered·2015
Same author

Bacterial proteins and peptides in cancer therapy: today and tomorrow.

Bioengineered·2014
Same author

Genome Sequence of the 2,4,5-Trichlorophenoxyacetate-Degrading Bacterium Burkholderia phenoliruptrix Strain AC1100.

Genome announcements·2013
Same author

Engineering of bacterial strains and their products for cancer therapy.

Applied microbiology and biotechnology·2013

Related Experiment Video

Updated: May 2, 2026

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
09:09

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

Published on: November 16, 2016

7.3K

Microbial pathogenicity: a new approach to drug development.

Ananda M Chakrabarty1

  • 1Department of Microbiology and Immunology, University of Illinois College of Medicine, 835 South Wolcott Avenue, Chicago, IL, 60612, USA, pseudomo@uic.edu.

Advances in Experimental Medicine and Biology
|March 6, 2014
PubMed
Summary
This summary is machine-generated.

Certain bacterial pathogens residing in the human body may offer novel therapeutic compounds for developing next-generation anticancer and other drugs. This research explores the potential benefits derived from these disease-causing microorganisms.

More Related Videos

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.0K
A High-throughput, High-content, Liquid-based C. elegans Pathosystem
09:44

A High-throughput, High-content, Liquid-based C. elegans Pathosystem

Published on: July 1, 2018

14.2K

Related Experiment Videos

Last Updated: May 2, 2026

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
09:09

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

Published on: November 16, 2016

7.3K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.0K
A High-throughput, High-content, Liquid-based C. elegans Pathosystem
09:44

A High-throughput, High-content, Liquid-based C. elegans Pathosystem

Published on: July 1, 2018

14.2K

Area of Science:

  • Microbiology
  • Drug Discovery
  • Human Health

Background:

  • Pathogenic bacteria pose significant threats to human health, causing debilitating infectious diseases globally.
  • Non-communicable diseases like cancer and diabetes also result in substantial mortality and societal impact.

Purpose of the Study:

  • To explore the potential of bacterial pathogens residing in the human body as a source for novel therapeutic agents.
  • To demonstrate that beneficial applications, such as drug development, can emerge from studying pathogenic bacteria.

Main Methods:

  • Literature review and analysis of existing research on bacterial pathogens and their interactions within the human body.
  • Identification of specific bacterial species with long-term human residence.
  • Exploration of known or potential mechanisms by which these bacteria could yield therapeutic compounds.

Main Results:

  • Certain bacterial pathogens harbor unique biochemical pathways and produce metabolites with potential medicinal properties.
  • Long-term residence of specific bacteria may involve interactions that can be harnessed for therapeutic purposes.
  • The study highlights a paradigm shift in viewing pathogens as potential sources of beneficial drugs.

Conclusions:

  • Bacterial pathogens, often viewed solely as threats, represent a promising, yet underexplored, resource for next-generation drug discovery.
  • Further research into the symbiotic and pathogenic interactions of bacteria within the human microbiome could unlock novel treatments for cancer and other diseases.